Beginning Cash: The amount of cash reported by the company on its previous statement.
Enliven Therapeutics, Inc. (ELVN) had Beginning Cash of $124.17M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-25.34M |
|
-- |
|
-- |
|
$28.58M |
|
$-28.58M |
|
$3.25M |
|
$-25.34M |
|
$-25.34M |
|
$-25.34M |
|
$-25.34M |
|
$-25.34M |
|
$-25.34M |
|
$-28.58M |
|
$-28.43M |
|
52.11M |
|
52.11M |
|
$-0.49 |
|
$-0.49 |
|
| Balance Sheet Financials | |
$495.62M |
|
$0.46M |
|
$8.27M |
|
$503.89M |
|
$15.21M |
|
-- |
|
$0.20M |
|
$15.41M |
|
$488.47M |
|
$488.47M |
|
$488.47M |
|
59.23M |
|
| Cash Flow Statement Financials | |
$-41.18M |
|
$-182.16M |
|
$218.61M |
|
|
Beginning Cash |
$124.17M |
$119.44M |
|
$-4.73M |
|
$14.52M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
32.58 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-41.34M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-5.19% |
|
-5.19% |
|
-5.03% |
|
-5.19% |
|
$8.25 |
|
$-0.79 |
|
$-0.79 |
|